株探米国株
英語
エドガーで原本を確認する
false 0001641631 0001641631 2024-02-28 2024-02-28 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): February 28, 2024

 

Beyond Air, Inc.

(Exact Name of Registrant as Specified in Its Charter)

 

Delaware   001-38892   47-3812456

(State or Other Jurisdiction

of Incorporation)

  (Commission
File Number)
  (IRS Employer
Identification No.)

 

900 Stewart Avenue, Suite 301

Garden City, NY 11530

(Address of Principal Executive Office)

 

516-665-8200

(Registrant’s telephone number, including area code)

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR240.14d-2(b))
   
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $.0001 per share   XAIR   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

Item 1.01 Entry into a Material Definitive Agreement.

 

On February 28, 2024, Beyond Air, Inc. (the “Company”) entered into an Amendment No. 1 (the “Amendment”) to the At-The-Market Equity Offering Sales Agreement, dated February 4, 2022 (as amended, the “Sales Agreement”), by and among the Company, Truist Securities, Inc. and Oppenheimer & Co. Inc. (“Oppenheimer”), as sales agents (the “Agents”). The purpose of the Amendment is to terminate the participation of Oppenheimer as an Agent.

 

The foregoing description of the Amendment does not purport to be complete and is qualified in its entirety by reference to the text of the Amendment, which is filed herewith as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.

 

This Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), nor shall there be any offer, solicitation or sale of the Common Stock in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit
No.
  Description
     
10.1   Amendment No. 1 to Sales Agreement, dated February 28, 2024, by and among Beyond Air, Inc. and Truist Securities, Inc. and Oppenheimer & Co. Inc.
104   Cover Page Interactive Data File (formatted as Inline XBRL).

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  BEYOND AIR, INC.
     
Date: March 1, 2024 By: /s/ Steven A. Lisi
    Steven A. Lisi
    Chief Executive Officer

 

 

 

 

 

EX-10.1 2 ex10-1.htm

 

Exhibit 10.1

 

AMENDMENT NO. 1 TO SALES AGREEMENT

 

February 28, 2024

 

Truist Securities, Inc.
3333 Peachtree Road, 11th Floor
Atlanta, Georgia 30326

 

Oppenheimer & Co. Inc.
85 Broad Street
New York, New York 10004

 

Ladies and Gentlemen:

 

Beyond Air, Inc., a Delaware corporation (the “Company”), together with Truist Securities, Inc. (“Truist”) and Oppenheimer & Co. Inc. (“Oppenheimer”), are parties to that certain Sales Agreement dated February 4, 2022 (the “Agreement”). All capitalized terms not defined herein shall have the meanings ascribed to them in the Agreement.

 

The Company desires to amend the Agreement as set forth in this Amendment No. 1 thereto (this “Amendment”) to terminate the participation of Oppenheimer as an agent (the “Prior Agent”) in the offering of Placement Shares under the Agreement as follows:

 

1. The definition of “Agents” in the Agreement is hereby amended to delete Oppenheimer, and all references to “Agents” and “Designated Agent” in the Agreement are intended to reference solely Truist as the single remaining Agent unless and until the Agreement is further amended to add any additional sales agents.

 

2. Section 12 of the Agreement is hereby amended to delete the name and address of the Prior Agent.

 

3. Each of Schedule 1 and Schedule 2 to the Agreement are hereby amended to delete all references to the Prior Agent.

 

4. Except as specifically set forth herein, all other provisions of the Agreement shall remain in full force and effect.

 

5. As of the date of this Amendment, the parties agree that the Prior Agent shall no longer be considered to be an Agent or Designated Agent under the Agreement, and all of its rights and obligations under the Agreement are hereby terminated, provided, that the provisions of the Agreement that survive termination shall remain in full force and effect for the Prior Agent notwithstanding such termination; and provided, further, that the consent of the Prior Agent shall not be required for any amendment or modification to or waiver of any provision of the Agreement except for any amendment or modification to or waiver of any of the provisions of the Agreement that remain in full force and effect with regard to the Prior Agent and that would adversely affect the rights of the Prior Agent.

 

 

 

6. This Amendment together with the Agreement (including all exhibits attached hereto) constitutes the entire agreement and supersedes all other prior and contemporaneous agreements and undertakings, both written and oral, among the parties hereto with regard to the subject matter hereof. Neither this Amendment nor any term hereof may be amended except pursuant to a written instrument executed by the Company, Truist and Oppenheimer. In the event that any one or more of the provisions contained herein, or the application thereof in any circumstance, is held invalid, illegal or unenforceable as written by a court of competent jurisdiction, then such provision shall be given full force and effect to the fullest possible extent that it is valid, legal and enforceable, and the remainder of the terms and provisions herein shall be construed as if such invalid, illegal or unenforceable term or provision was not contained herein, but only to the extent that giving effect to such provision and the remainder of the terms and provisions hereof shall be in accordance with the intent of the parties as reflected in this Amendment. All references in the Agreement to the “Agreement” shall mean the Agreement as amended by this Amendment; provided, however, that all references to “date of this Agreement” in the Agreement shall continue to refer to the date of the Agreement.

 

7. The Company, Truist and Oppenheimer hereby irrevocably waive any right either may have to a trial by jury in respect of any claim based upon or arising out of this Amendment.

 

8. This Amendment shall be governed by, and construed in accordance with, the internal laws of the State of New York without regard to the principles of conflicts of laws. Each party hereby irrevocably submits to the non-exclusive jurisdiction of the state and federal courts sitting in the City of New York, borough of Manhattan, for the adjudication of any dispute hereunder or in connection with any transaction contemplated hereby, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is brought in an inconvenient forum or that the venue of such suit, action or proceeding is improper. Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof (certified or registered mail, return receipt requested) to such party at the address in effect for notices to it under this Amendment and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any manner permitted by law.

 

9. This Amendment may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Delivery of an executed Amendment by one party to the other may be made by facsimile or email transmission.

 

[Remainder of Page Intentionally Blank]

 

 

 

If the foregoing correctly sets forth the understanding between the parties, please so indicate in the space provided below for that purpose, whereupon this Amendment shall constitute a binding amendment to the Agreement.

 

Very truly yours,
     
  BEYOND AIR, INC.
   
  By: /s/ Steve Lisi
  Name: Steve Lisi
  Title: CEO

 

Confirmed as of the date first above mentioned:

 

TRUIST SECURITIES, INC.    
     
By: /s/ Keith Carpenter  
Name: Keith Carpenter  
Title: Managing Director  
     
OPPENHEIMER & CO. INC.    
     
By: /s/ Michael Margolis  
Name: Michael Margolis R.Ph.  
Title: Senior Managing Director, Co-Head Healthcare IB